Lilly Wants To Gamble On Dice’s Oral IL-17 Drugs For Psoriasis

Lilly agrees to pay about $2.4bn to acquire Dice and its Phase IIb oral IL-17 inhibitor, as well as a discovery platform that has yielded a preclinical oral PD-L1 inhibitor.

Tumbling dice
Lilly is rolling the dice on oral IL-17 inhibitors in psoriasis • Source: Shutterstock

In a deal that may bring Eli Lilly and Company an oral alternative to blockbuster Taltz (ixekizumab) for psoriasis, the Indianapolis pharma unveiled an agreement on 20 June to acquire DICE Therapeutics, Inc. for approximately $2.4bn, the sixth-largest biopharmaceutical M&A deal of 2023.

Under the deal, expected to close in Q3, Lilly would acquire Dice’s pipeline of oral interleukin-17 inhibitors as well as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.